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Objectives To determine safety and efficacy of the 5HT1A serotonin partial agonist buspirone on core autism and
associated features in children with autism spectrum disorder (ASD).
Study designChildren 2-6 years of agewith ASD (N = 166) were randomized to receive placebo or 2.5 or 5.0mg of
buspirone twice daily. The primary objective was to evaluate the effects of 24 weeks of buspirone on the Autism
Diagnostic Observation Schedule (ADOS) Composite Total Score. Secondary objectives included evaluating the
effects of buspirone on social competence, repetitive behaviors, language, sensory dysfunction, and anxiety and
to assess side effects. Positron emission tomography measures of tryptophan metabolism and blood serotonin
concentrations were assessed as predictors of buspirone efficacy.
Results There was no difference in the ADOS Composite Total Score between baseline and 24 weeks among
the 3 treatment groups (P = .400); however, the ADOS Restricted and Repetitive Behavior score showed a
time-by-treatment effect (P = .006); the 2.5-mg buspirone group showed significant improvement (P = .003),
whereas placebo and 5.0-mg buspirone groups showed no change. Children in the 2.5-mg buspirone group
were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission
tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044). Adverse events did not differ
significantly among treatment groups.
Conclusions Treatment with 2.5 mg of buspirone in young children with ASDmight be a useful adjunct therapy to
target restrictive and repetitive behaviors in conjunction with behavioral interventions. (J Pediatr 2016;170:45-53).
Trial registration ClinicalTrials.gov: NCT00873509.
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1-PP 1-pyrimidylpiperazine
ABC Aberrant Behavior Checklist
ADI-R Autism Diagnostic Interview-
Revised
ADOS Autism Diagnostic Observation
Schedule
ADOS-CTS Autism Diagnostic Observation
Schedule Composite Total
Score
ADOS-RRB ADOS Restricted and
Repetitive Behavior
ADOS-SA Autism Diagnostic Observation
Schedule Social Affect
AMT a[11C]methyl-L-tryptophan
ASD Autism spectrum disorder
PET Positron emission tomography
RBS Repetitive Behaviors Scale-
Revised
SUV Standard uptake value
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imaging data in children with ASD that demonstrated a
deviation from the normal developmental time course of
changes in serotonin synthesis measured by the tryptophan
analog a[11C]methyl-L-tryptophan (AMT) on positron
emission tomography (PET) imaging.14,15 Because serotonin
function is important in postnatal brain development,16 we
hypothesized that one approach to the treatment of core
features of ASD pharmacologically would be the use of
serotonin agonists in children younger than 6 years of age,
when their brain serotonin synthesis capacity is lower than
in children without ASD. Agonists of the 5HT1A receptor
have been shown to improve social function in disparate
animal models of ASD.17-19
In the present study, the 5HT1A serotonin partial agonist
buspirone was used to target core symptoms during the
developmental period of low serotonin synthesis capacity
in children with ASD as measured with PET. For this study,
we chose the 5HT1A serotonin partial agonist buspirone for a
number of reasons. Several small studies of buspirone in
older children with autism showed efficacy in some children,
with low incidence of adverse events.20-22 Furthermore,
buspirone is approved by the Food and Drug Administration
for the treatment of anxiety in children, and anxiety
increasingly is recognized as a comorbid condition in
ASD.23 Previously, we had assessed the disposition of
buspirone in 2- to 6-year-old children to establish dosing
guidelines for this population.24 Children with a diagnosis
of autism received a single, oral dose of buspirone solution
(2.5 mg or 5.0 mg). We found plasma concentrations and
pharmacokinetic measurements for buspirone and the
metabolite 1-pyrimidylpiperazine (1-PP) with 2.5-5.0 mg
doses to be similar to values observed in older children
receiving 7.5-15.0 mg doses. In the present study, before
drug treatment, subjects underwent PET scanning and blood
studies to evaluate whether the response to buspirone can
be predicted by brain tryptophan metabolism or blood
serotonin levels.Methods
The study and was conducted at 6 academic medical centers:
Wayne State University School of Medicine, Children’s
Hospital of Michigan; Case Western Reserve University,
Rainbow Babies Hospital; University of Texas Southwestern;
Cleveland Clinic Foundation; University of California Davis;
and New York University School of Medicine. All study-site
institutional review boards approved the study, and written
informed consent was obtained for each participant from
at least 1 parent or legal guardian. The National Institutes
of Neurological Disorders and Stroke established a Data
and Safety Monitoring Board to monitor the trial.
Participants (N = 166, 2 to <6 years) with ASD were
included based on criteria from the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision, the
Autism Diagnostic Interview-Revised (ADI-R),25 and the46Autism Diagnostic Observation Schedule (ADOS)26 via use
of the revised algorithms27 with the following cutoff scores
for the ADOS: Module 1, no words cutoff = 14; Module 1,
some words cutoff = 10; Module 2, younger cutoff = 8;
Module 2, older cutoff = 8; Module 3, cutoff = 7. Exclusion
criteria were the presence or history of neurologic disorders,
including seizure disorders, phenylketonuria, tuberous
sclerosis complex, Rett syndrome, Fragile X syndrome,
Down syndrome, and traumatic brain injury, and other
medical or behavioral problems that required medications
that are centrally active. Additional exclusion criteria were
renal or hepatic disease, treatment with drugs known to alter
the activity of CYP3A4, use of centrally acting drugs during
the 6 weeks before or during the study, and previous
treatment for periods longer than 2 weeks with buspirone
or selective serotonin reuptake inhibitors. Participants who
used a stable dose of melatonin for sleep before entry into
the study were allowed to continue use during the study.
Treatment
Buspirone hydrochloride U.S.P. (Fermion, Espoo, Finland)
or placebo dissolved in Orasweet (2.5 mg/mL or 5.0 mg/
mL; Paddock Laboratories Inc, Minneapolis, Minnesota)
was administered once per day in the evening for the first
week of treatment and thereafter twice a day, approximately
12 hours apart, for 23 weeks during the placebo-controlled
phase. Patients who received buspirone during the first phase
were continued on the same dose during the second phase.
Patients receiving placebo were randomized to 2.5 mg or
5.0 mg buspirone for the 24-week second phase. Within
each site, participants were randomized in blocks for age
groups (2 to <4 years and 4 to <6 years) to treatment groups
of 2.5 mg, 5 mg, or placebo. Drug compliance, as assessed by
measuring the volume of unused drug, showed that for 61%
of the subjects there was 100% compliance, 27% had
compliance between 90% and 100%, 7% had compliance
between 80% and 90%, and 4% had less than 80%
compliance. All site personnel were blinded to treatment
during both phases of treatment. A medical monitor at a
different site not involved in the enrollment of participants
evaluated the adverse events.
Efficacy Measures
Efficacy measures assessed at baseline, 24 weeks, and 48 weeks
included scores derived from several measures, including the
ADOS, Vineland Adaptive Behavior Scales-Second Edition,28
Aberrant Behavior Checklist (ABC),29,30 Repetitive Behaviors
Scale-Revised (RBS),31 Sensory Profile Scale,32 Leiter
Parent-Report,33 and the Children’s Yale Brown Obsessive
Compulsive Scale, Modified for Pervasive Developmental
Disorders.34 Global cognitive functioning was measured at
baseline by the use of either the Mullen Scales of Early
Learning35 or the Differential Abilities Scales-Second
Edition.36 Clinicians who completed research training were
required to demonstrate 90% reliability with a consensus-
coded protocol of an ADI-R recording and 80% reliability
with a consensus coded protocol of a Module 1 or 2 andChugani et al
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for fidelity, and clinicians were given written feedback
regarding the fidelity of their administrations and coding.
PET Scan Protocol and Image Data Analyses
PET studies with the tracer AMT were performed before
treatment with the use of an EXACT/HR whole-body posi-
tron tomography (CTI/Siemens, Knoxville, Tennessee) at
Children’s Hospital of Michigan as previously described.14
The calculation of the unidirectional uptake rate constant
for AMT (K-complex) was obtained via the Patlak graphical
approach.37 Standard uptake value (SUV) images were used
to determine whether there were focal regions of increased
AMT uptake. A nuclear medicine physician blinded to
treatment results assessed each SUV scan and tabulated the
location(s) of increased AMT uptake. For comparison with
outcome, the data were coded from 0 to 3 to indicate the
number of regions of focal increased tracer uptake in each
participant. Furthermore, visual analyses for focal AMT
uptake were verified by semiquantitative assessment in basal
ganglia and thalamus by obtaining mean SUV bilaterally for
manually defined regions of interest.
Adverse Events and Laboratory Measures
Adverse events were assessed monthly with the Safety
Monitoring Uniform Report Form and once between
monthly visits using a structured interview. Pulse, blood
pressure, and weight were measured monthly. A physical
examination was conducted at baseline, 4, 24, 28, and
48 weeks. Hematology, renal function, and liver function
laboratory tests, and buspirone and 1-PP levels were
measured at 4, 12, 24, 28, 36, and 48 weeks as described
previously.24 Mean buspirone levels for cases in which drug
was detected were 0.14  0.24 ng/mL for the 2.5-mg group
and 0.22  0.55 ng/mL for the 5.0-mg group. Mean 1-PP
levels for cases in which drug was detected were
0.78  0.87 ng/mL for the 2.5-mg group and
1.08 1.22 ng/mL for the 5.0-mg group. Blood for serotonin
concentration was collected at baseline and assayed by
high-pressure liquid chromatography by ARUP Laboratories
(Salt Lake City, Utah; coefficient of variation = 8.9, normal
range less than 220 ng/mL).
Statistical Analyses
To assess the primary outcome of the impact of buspirone on
the ADOS Composite Total Score (ADOS-CTS), we per-
formed a 3  2 mixed-design ANOVA with the 3 treatment
groups as between-subjects factors and the 2 assessment time
points (baseline and 24 weeks) as the within-subjects factor.
Secondary outcomes included social competence and
deviance (ADOS Social Affect [ADOS-SA] score, Vineland
socialization domain, ABC scale II), language competence
and deviance (Vineland communication domain, ABC scale
V), repetitive behavior (ADOS Restricted and Repetitive
Behavior [ADOS-RRB] score, RBS total score, Children’s
Yale Brown Obsessive Compulsive Scale, Modified for
Pervasive Developmental Disorders total score), anxietyEfficacy of Low-Dose Buspirone for Restricted and Repetitive Be
Autism Spectrum Disorder: A Randomized Trial(composite of ABC scale I and Leiter Emotion regulation
score), and sensory processing (Sensory Profile, Multisensory
score) by use of the same statistical analysis as the
primary objective. Measures were analyzed separately and
as composites.
Brain and blood serotonin biomarker predictor analyses
included K-complex values and the number of focally
increased AMT SUV based on AMT PET imaging and blood
serotonin concentration measured at baseline. For outcomes
that showed an improvement attributable to treatment with
buspirone, the change from baseline to 24 weeks was
calculated as an improvement score. Each of the outcome
variables was analyzed separately. To determine whether
improvement was related to K-complex, number of regions
of focally increased AMT uptake and blood serotonin,
bivariate analyses, and linear multiple regression were
performed. Statistical analysis for adverse events was grouped
into classes, differences between the groups were tested with
the Fisher exact test. The SAS program Proc freq (SAS
Institute Inc, Cary, North Carolina) was used with the option
of exact chisq.
Results
Enrollment for the study began on July 14, 2009, and was
completed on January 8, 2013. Two hundred ten children
were consented and assessed for eligibility into the study,
and 166 eligible children were enrolled in the study and
randomized to 3 treatment groups: 2.5 mg buspirone
(n = 54), 5.0 mg buspirone (n = 55), and placebo (n = 57)
(Figure 1; available at www.jpeds.com). Twenty-four
participants (14%) discontinued the study during the
treatment phase (adverse event [n = 12, 6 in the placebo
group, 3 in the 2.5-mg group, 3 in the 5.0-mg group],
withdrew consent [n = 3], lost to follow-up [n = 3], started
exclusionary medication [n = 2], clinical decision [n = 2],
participant moved [n = 1], time commitments [n = 1]).
Outcome data could not be obtained for 11 of 24 subjects
who discontinued early because families declined to return
for the final visit testing or were lost to follow-up (3 in the
2.5-mg group, 3 in the 5.0-mg group, and 5 in placebo
group). Of the 142 participants who completed the first
phase of the trial, 138 were rerandomized to the second
phase (Figure 1). The 2.5-mg, 5.0-mg, and placebo groups
showed no significant differences at baseline in sex, age,
ethnicity or race, ADOS, ADI-R, Vineland Adaptive Scale
age equivalents, and Mullen Scales of Early Learning or
Differential Abilities Scales-Second Edition (Table I).
Efficacy
ADOS-CTS, ADOS-SA, and ADOS-RRB Scores. For
the main outcome measure, there was significant
improvement with time (P = .002) but no difference in the
change in ADOS-CTS scores between baseline and 24 weeks
among the 3 treatment groups (P = .400; Table II). For the
secondary outcomes, the ADOS-SA scores showed
significant improvement with time (P = .006) but nohavior in Young Children with 47
Table I. Participant demographics and baseline group characteristics
Characteristics 2.5 mg (n = 54) 5.0 mg (n = 55) Placebo (n = 57) P value
Sex, n (%)
Female 8 (15) 11 (20) 10 (18) .779
Male 46 (85) 44 (80) 47 (82)
Age, 2 to <4 y
n 25 23 25 .475
Mean (SD) 2.5 (0.51) 27 (0.49) 2.7 (0.48)
Age, 4 to <6 y
n 29 32 32 .129
Mean (SD) 4.4 (0.50) 4.5 (0.51) 4.3 (0.46)
Ethnicity, n (%)
Hispanic or Latino 9 (17) 3 (5) 4 (7) .237
Not Hispanic or Latino 44 (81) 52 (95) 53 (93)
Unknown or not reported 1 (2) 0 (0) 0 (0)
Race
American Indian or Alaskan 1 (2) 0 (0) 0 (0) .718
Asian 1 (2) 0 (0) 1 (2)
Black or African American 17 (31) 18 (33) 16 (28)
Hawaiian or Pacific Islander 1 (2) 1 (2) 1 (2)
White 31 (57) 31 (56) 35 (61)
More than one race 2 (4) 5 (9) 2 (4)
Unknown or not reported 1 (2) 0 (0) 2 (4)
ADOS Module 1: no words
n 20 22 27 .358
Mean (SD) 21.9 (3.29) 20.5 (2.97) 21.7 (3.86)
ADOS Module 1: some words
n 22 23 18 .468
Mean (SD) 17.5 (4.70) 17.3 (3.44) 18.8 (4.49)
ADOS Module 2: Younger
n 7 4 9 .956
Mean (SD) 14.4 (3.64) 15.3 (4.65) 14.4 (5.59)
ADOS Module 2: Older
n 0 3 2 .087
Mean (SD) 0 15.7 (3.79) 23.0 (1.41)
ADOS Module 3: Total
n 5 3 1 .413
Mean (SD) 12.4 (6.19) 16.3 (3.21) 8.0
ADI-R-A
n 54 55 57 .621
Mean (SD) 19.3 (4.73) 18.4 (5.21) 19.1 (4.52)
ADI-R-B (Verbal)
n 22 22 24 .398
Mean (SD) 16.5 (4.07) 15.1 (3.35) 15.6 (2.95)
ADI-R-B (Non-Verbal)
n 32 33 33 .889
Mean (SD) 11.7 (2.12) 11.8 (2.05) 11.6 (2.24)
ADI-R-C
n 54 55 57 .739
Mean (SD) 5.7 (2.38) 5.5 (2.33) 5.9 (2.05)
Differential Abilities Scale score
n 4 3 4 .952
Mean (SD) 71.8 (40.62) 65.3 (33.62) 63.8 (36.88)
Mullen Scales of Early Learning
n 33 34 35 .862
Mean (SD) 62.5 (18.80) 64.6 (23.90) 65.2 (21.73)
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 170difference between treatment groups (P = .865). In contrast,
the ADOS-RRB scores showed a significant time by
treatment effect (P = .006). There was evidence of an
improvement in the 2.5-mg group (P = .003), and the
5.0-mg group (P = .122), and the placebo group (P = .346)
showed no change over time (Figure 2, A).
Secondary Measures. There was a significant time by
treatment effect on the RBS total score (P = .017; Table II).
The 2.5-mg group showed improvement (P < .001), and48the placebo (P = .197) and 5.0-mg (P = .437) groups
showed no significant change during the treatment period.
At baseline, however, the 2.5-mg group was significantly
worse on the RBS than the 5.0-mg (P = .002) and placebo
(P = .040) groups, but at 24 weeks these groups were no
longer statistically different (P = .082 and P = .405,
respectively). The Anxiety Composite showed a significant
time by treatment effect (P = .041; Table II). For the
Anxiety Composite score, the 2.5-mg group (P < .001) and
the placebo group (P = .004) showed improvement, andChugani et al
Table II. ADOS Results and Secondary Outcomes
Placebo,
baseline
Placebo,
24 wk
2.5 mg,
baseline
2.5 mg,
24 wk
5.0 mg,
baseline
5.0 mg,
24 wk
Significance
time by
treatment
ADOS-CTS 19.6 (0.6) 18.6 (0.7)
.039
18.3 (0.7) 16.2 (0.7)
.009
18.4 (0.6) 17.9 (0.7)
.431
.400
.002
ADOS-SA 15.0 (0.5) 14.1 (0.6)
.069
13.9 (0.5) 13.3 (0.6)
.242
14.2 (0.5) 13.4 (0.6)
.063
.865
.006
ADOS-RRB 4.7 (0.3) 4.4 (0.3)
.346
4.4 (0.3) 3.5 (0.03)
.003
4.1 (0.3) 4.6 (0.3)
.122
.006
.154
Social Competence (Vineland socialization domain) 70.4 (1.5) 72.4 (1.7)
.255
68.7 (1.5) 70.4 (1.7)
.228
71.0 (1.5) 72.3 (1.7) .982
.057
Social deviance (ABC scale II) 14.2 (1.2) 11.0 (1.1)
.001
15.3 (1.2) 12.1 (1.1)
.001
11.8 (1.2) 10.6 (1.1)
.218
.204
<.001
Language Competence (Vineland communication
domain)
68.5 (2.2) 69.7 (2.2)
.418
65.5 (2.2) 68.2 (2.3)
.052
70.6 (2.2) 72.7 (2.2)
.119
.709
.013
Language deviance (ABC Subscale V) 3.8 (0.5) 3.9 (0.5)
.682
4.4 (0.5) 4.1 (0.5)
.288
3.7 (0.5) 3.5 (0.4)
.728
.579
.560
Repetitive behavior (RBS total) 36.7 (3.5) 34.2 (3.2)
.197
46.9 (3.5) 38.0 (3.3)
<.001
31.5 (3.5) 29.9 (3.3)
.437
.017
<.001
Compulsive behaviors (CYBOCS total score) 11.9 (0.6) 11.2 (0.6)
.143
12.1 (0.6) 11.1 (0.6)
.052
11.5 (0.6) 10.7 (0.6)
.104
.936
.004
Anxiety composite score (ABC subscale I, Leiter
emotion regulation)
0.008 (0.1) 0.242 (0.1)
.004
0.536 (0.1) 0.118 (0.1)
<.001
0.014 (0.1) 0.120 (0.1)
.214
.041
<.001
Sensory processing (Sensory Profile Multisensory score) 65.4 (3.7) 66.7 (3.6)
.678
58.6 (3.8) 59.6 (3.6)
.750
67.2 (3.7) 68.1 (3.5)
.776
.995
.557
CYBOCS, Children’s Yale Brown Obsessive Compulsive Scale, Modified for Pervasive Developmental Disorders.
Values are mean (SD), and P value unless otherwise stated. Bold values indicate statistical significance.
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(P = .214) group. Similar to the RBS score, the 2.5-mg
group was significantly worse at baseline for the Anxiety
Composite compared with the 5.0-mg and placebo groups.
None of the other measures showed significant time by
treatment effects.
Brain AMT PET and Plasma Serotonin as Predictors
of Drug Response. Whole-brain serotonin synthesis
capacity (K-complex) and presence of focal regions showing
elevated AMT SUV in basal ganglia, thalamus, cerebellum,
and brainstem were assessed on AMT PET scans, which
were acquired in 119 of the study participants, 39 of whom
were in the 2.5-mg buspirone group. The whole-brain
serotonin synthesis (K-complex) ranged from 0.003 to
0.008 g/mL in the 119 children. In the 2.5-mg buspirone
group, the mean K-complex was 0.00581 g/mL for those
who improved on the ADOS-RRB and 0.00539 g/mL for
those who did not show an improvement (P = .399). For
the entire sample having a PET scan (N = 119), 65 showed
at least 1 focal region with increased AMT uptake. Focal
abnormalities were present in basal ganglia (N = 27),
thalamus (N = 24), cerebellum (N = 27), and brainstem
(N = 26) (Figure 2, B and D). The 2.5-mg buspirone group
was coded as 0 (n = 16), 1 (n = 13), 2 (n = 7), and 3
(n = 3), according to the number of focal increases present
in each child. The mean SUV for focal increases in basal
ganglia was 0.509  0.095 SD, and the mean SUV was
0.489  0.086 SD for the contralateral region. For the
thalamus, increased focal regions had a mean SUV of
0.519  0.091 compared with the contralateral side, with a
mean SUV of 0.499  0.087. In subjects with no focal
Efficacy of Low-Dose Buspirone for Restricted and Repetitive Be
Autism Spectrum Disorder: A Randomized Trialincreases of AMT uptake, mean SUVs for basal ganglia
(left: 0.467  0.081, right: 0.471  0.083) and thalamus
(left: 0.471  0.087, right: 0.473  0.085) were similar to
regions with lower AMT SUV in cases with asymmetry. In
a bivariate analysis, the number of focal increases of AMT
SUV in the 2.5-mg group was significantly related to
improvement on the ADOS-RRB score (r = 0.38,
P = .018, n = 39). Fewer focal abnormalities were
associated with more improvement (Figure 2, B).
Elevated blood serotonin concentration was defined as
greater than220ng/mLby the clinical laboratory. For the entire
sample, N = 60 showed elevated blood serotonin (Figure 2, C).
When a t test was used to compare improvement in the
ADOS-RRB score for elevated (n = 19) or nonelevated
plasma serotonin (n = 31) subjects in the 2.5-mg buspirone
group, the subjects with normal blood serotonin
concentrations were significantly more likely to improve on
the ADOS-RRB score than those with elevated blood
serotonin (t = 2.066, P = .044, n = 50). In a multiple
regression analysis predicting improvement on the
ADOS-RRB (n = 39), the number of focal increases in AMT
SUV remained a significant predictor (P = .025), but
dichotomous blood serotonin did not (P = .117). The sample
size for the multiple regression was smaller because blood
serotonin cases in the multiple regression included only
those patients who had PET scans, and this may account for
less power to detect an effect of blood serotonin as a
significant predictor.
Adverse Events
There was no significant difference in occurrence of any
adverse events among the 3 groups (P = .145; Table IIIhavior in Young Children with 49
Figure 2. A, Estimated marginal means for the ADOS-RRB Scale at baseline and after 24 weeks for the 3 treatment groups.
B, Improvement in the 2.5 mg group was significantly related to the number of brain regions showing focal increases in AMT
SUVs. C, Distribution of blood serotonin concentration. D, AMT SUV Images. The left column displays images from a child with
no focal increases in tracer SUV. The other 3 columns show images from childrenwith focally increased tracer uptake denoted by
arrows in basal ganglia, thalamus, brainstem and cerebellum. Rt, right; Lt, left.
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significant difference in the occurrence of adverse events in
the second phase of the study among the treatment groups,
including those who were on placebo during the first
24 weeks and subsequently started the drug, compared with
those who were taking the drug for the full 48 weeks
(P = .600; Table IV available at www.jpeds.com). This
finding suggests that long-term treatment with buspirone
up to 48 weeks is not associated with increased adverse
events. It is notable that there were no differences between
the placebo and treatment groups in behavioral activation
side effects that have been reported with selective serotonin
reuptake inhibitors.3850Discussion
Analyses of the main study outcome indicate that even
though buspirone treatment in young children with ASD
does not result in decreased overall symptoms of autism as
measured by the ADOS-CTS, secondary outcome measures
demonstrate significant improvement in repetitive and
restricted behaviors on the ADOS-RRB score in children
with ASD taking 2.5 mg of buspirone. Buspirone is a
5HT1A partial agonist at both the presynaptic somatoden-
dritic autoreceptors as well as postsynaptic receptors.39-42 A
body of literature in animal models has indicated that
when used in low doses, 5HT1A agonists preferentiallyChugani et al
March 2016 ORIGINAL ARTICLESactivate presynaptic autoreceptors, whereas greater doses are
required to stimulate the postsynaptic receptors.43-46 Thus,
the dose dependency for the actions of 5HT1A agonists is
attributable to different effects at presynaptic and postsyn-
aptic receptors. This finding is illustrated in studies in rats,
where low doses of the 5HT1A agonist 8-OHDPAT specific
for the presynaptic receptor suppress locomotion47,48 and
greater doses actually increase locomotion.44,49 Similarly, a
low dose (1 mg/kg) of buspirone, but not a greater dose
(2.0 mg/kg), attenuated apomorphine-induced locomotor
stereotypy in rats.50 Buspirone also shows dose dependency
in improving social behaviors in animal models of ASD.
For example, female prairie voles injected with 8 mg/kg
buspirone displayed partner preference, whereas those
administered saline or 30 mg/kg buspirone failed to show
partner preference.18 Furthermore, buspirone (2 mg/kg)
was shown to increase social behavior in the black and tan,
brachyuric autism mouse model.17 On the basis of these
studies, we suggest that preferential stimulation of the
presynaptic autoreceptor could explain why the 2.5-mg
buspirone group but not the 5.0-mg buspirone group showed
improvement on repetitive and restricted behaviors in our
study. In addition to activity at the 5HT1A receptor,
buspirone also has activity at the dopamine D2 receptor at
greater doses.29,45,46 Activity of buspirone at the D2 receptor
may be responsible for loss of the drug effect on stereotyped
behavior at the greater dose. Thus, the development of new
5HT1A agonists without D2 activity might be more effective
in treating stereotypy, as well as social symptoms and anxiety.
A recent report of a new orally active phenylaminotetralin-
chemotype dual 5HT1A and 5HT7 receptor partial agonist
was effective in decreasing motor stereotypy and increasing
social interactions with greater efficacy at greater doses in
multiple mouse models.51
There are several limitations with regard to the study and
its outcome. The first is that the ADOS, the tool used to
measure the main outcome, was not designed to measure
improvement in the severity of ASD. The ADOS is
considered the gold standard for the diagnosis of ASD, and
it has been shown to provide stability of diagnosis over
time.52 Indeed, several recent studies have demonstrated
the diagnostic stability of ADOS in children as young as
15 months of age.53,54 Our study included children as young
as 2 years of age. The stability of diagnosis for ASD was
demonstrated to be high in toddlers, and there was change
with time in the ADOS-SA and -RRB scores.54 Thus, in
that study, SA scores tended to improve at a follow-up of
at least 12 months, and the RRB scores tended to worsen.
The SA scores in our study also improved at 24 weeks’
follow-up in all treatment groups, but this improvement
did not differ significantly among the treatment groups.
The detection of a drug effect on the ADOS-SA might be
hindered by the tendency for this measure to improve in
this age group regardless of treatment. For the ADOS-RRB
scores, the placebo group and 5.0-mg buspirone groups
showed either no change or tended to worsen, consistent
with the report of age-related worsening in this domain. InEfficacy of Low-Dose Buspirone for Restricted and Repetitive Be
Autism Spectrum Disorder: A Randomized Trialcontrast, the 2.5-mg buspirone group showed a significant
improvement on the ADOS-RRB at 24 weeks (Figure 2, A).
Buspirone has long been approved for the treatment of
anxiety in children and adults. Several studies have found a
relationship between restricted and repetitive behaviors and
anxiety.55,56 Determining anxiety in young children with
developmental delays relies on the observation of behavior
from which inferences of mood states are drawn. Our
anxiety composite included not only symptoms of anxiety
but also other mood states and regulation of affect. In the
present study, there was evidence for improvement on the
anxiety composite with 2.5 mg of buspirone, although the
placebo group also showed significant improvement for
anxiety. In addition, our study sample represents children
for whom the etiology of their ASD is not known. We had
no genetic measures that could be used to compare
outcome with genetic risk or drug metabolism, although
children with known genetic disorders such as tuberous
sclerosis complex and Fragile X were excluded.
Our results, which show high blood serotonin concentra-
tions in ASD, are consistent with the body of literature on
blood serotonin and ASD.58 The group with elevated blood
serotonin concentrations in our study was significantly less
likely to improve on the ADOS-RRB score. We also found
that fewer focal increases of AMT SUV were significantly
related to more improvement on the ADOS-RRB score in
the 2.5-mg buspirone group. Focal abnormalities shown on
AMT PET scans in subjects with ASD were first reported as
an asymmetry of AMT uptake in thalamus, dentate nucleus
of the cerebellum, and frontal cortex.15 Studies on brain
tissue obtained at resective surgery from patients without
autism but with tuberous sclerosis complex and intractable
epilepsy or from patients with brain tumors who had
undergone AMT PET scanning revealed that increased
AMT uptake may represent tryptophan metabolism by the
kynurenine pathway (which is related to brain inflammation)
rather than the pathway for serotonin synthesis.57,59
In the current study, semiquantitative analyses support
our visual assessment that the asymmetries in basal ganglia
and thalamus represent increased tryptophan metabolism,
because the mean SUV from cases with no asymmetry had
values that were closer to values of the lower side in cases
who did show asymmetry. This observation is intriguing in
light of accumulating evidence for a role of brain inflamma-
tion in ASD, as has been reported in both imaging and
neuropathology studies.60-62 Thus, the brain regions showing
focally increased AMT SUV may represent tryptophan meta-
bolism by the kynurenine pathway and brain inflammation.
If that were the case, and fewer focal increases of tryptophan
metabolism are related to more improvement in restricted
and repetitive behavior with 2.5 mg of buspirone treatment,
a greater number of focal increases may potentially be a
predictor of more improvement in ASD in future studies
that use anti-inflammatory treatments.
Restricted and repetitive behaviors in ASD have been
reported to interfere with learning and lead to family stress.56
Recent research indicates that early behavioral interventionhavior in Young Children with 51
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 170in young children is effective in improving socialization,
language skills, and adaptive behavior, as measured on the
Vineland Scales and IQ as measured with the Mullen Scales
of Early Learning, but not in improvement on the ADOS
or on the Repetitive Behavior Scale.63 The present study
has shown that low-dose buspirone reduced restricted and
repetitive behaviors in young children with ASD. Therefore,
this treatment might be considered for further exploration as
a useful adjunct therapy to target restrictive and repetitive
behavior in conjunction with early behavioral intervention,
which has been shown to be effective in improving
socialization, language skills and adaptive behavior, to
provide therapeutic coverage for the full range of autism
core features and adaptive skills in young children with
ASD. n
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Table III. Treatment emergent adverse events during first 24 wk
Body system and preferred term
A-2.5 mg (n = 54) B-5.0 mg (n = 55) C-Placebo (n = 57)
P value*
Subjects
Events
Subjects
Events
Subjects
Eventsn* (%) n* (%) n* (%)*
All adverse events 52 (96) 617 55 (100) 608 53 (93) 633 .1455
Psychiatric disorders 42 (78) 119 46 (84) 115 41 (72) 119 .3392
Aggression 23 (43) 30 15 (27) 19 22 (39) 25 .2183
Sleep disorder 14 (26) 16 19 (35) 26 13 (23) 19 .3826
Initial insomnia 9 (17) 9 10 (18) 12 11 (19) 14 .9674
Agitation 7 (13) 8 7 (13) 7 10 (18) 11 .7578
Terminal insomnia 5 (9) 6 13 (24) 15 5 (9) 7 .0481
Affect lability 8 (15) 9 7 (13) 10 4 (7) 4 .4035
Abnormal behavior 5 (9) 5 1 (2) 2 9 (16) 13 .0261
Anxiety 6 (11) 6 3 (5) 4 1 (2) 1 .0927
Respiratory disorders 38 (70) 118 38 (69) 134 41 (72) 137 .9765
Cough 25 (46) 48 23 (42) 44 28 (49) 49 .7277
Sinus congestion 12 (22) 19 19 (35) 38 18 (32) 30 .3370
Rhinorrhea 15 (28) 19 17 (31) 28 15 (26) 25 .8861
Nasal congestion 9 (17) 16 5 (9) 9 9 (16) 11 .4601
Epistaxis 4 (7) 8 3 (5) 3 7 (12) 16 .4411
General disorders 38 (70) 74 37 (67) 75 38 (67) 80 .9135
Pyrexia 31 (57) 47 24 (44) 42 29 (51) 50 .3581
Irritability 10 (19) 10 14 (25) 17 15 (26) 19 .5635
Gastrointestinal disorders 32 (59) 78 37 (67) 115 37 (65) 88 .6818
Vomiting 20 (37) 28 23 (42) 36 22 (39) 28 .9019
Diarrhea 18 (33) 27 22 (40) 30 20 (35) 28 .7737
Constipation 5 (9) 8 15 (27) 23 10 (18) 15 .0468
Infections and infestations 32 (59) 69 22 (40) 40 29 (51) 62 .1323
Ear infection 11 (20) 12 6 (11) 6 8 (14) 8 .3971
Upper respiratory tract infection 6 (11) 14 3 (5) 4 12 (21) 26 .0460
Nasopharyngitis 6 (11) 9 4 (7) 7 6 (11) 9 .8019
Nervous system disorders 26 (48) 46 26 (47) 36 26 (46) 41 .9804
Psychomotor hyperactivity 15 (28) 16 12 (22) 13 18 (32) 21 .5102
Somnolence 7 (13) 15 6 (11) 8 4 (7) 4 .5600
Nutrition disorders 25 (46) 34 23 (42) 29 22 (39) 26 .7088
Decreased appetite 17 (31) 20 11 (20) 13 13 (23) 15 .3662
Increased appetite 11 (20) 11 16 (29) 16 11 (19) 11 .4329
Skin disorders 18 (33) 22 16 (29) 23 19 (33) 28 .8735
Rash 8 (15) 8 8 (15) 11 7 (12) 10 .9220
Injury, poisoning, and procedural 7 (13) 12 6 (11) 7 8 (14) 9 .9171
Renal and urinary disorders 6 (11) 10 7 (13) 8 7 (12) 9 1.0000
Eye disorders 7 (13) 10 5 (9) 5 2 (4) 5 .1779
Immune system disorders 5 (9) 6 3 (5) 4 6 (11) 7 .6494
Investigations 1 (2) 4 8 (15) 8 5 (9) 5 .0493
Musculoskeletal disorders 5 (9) 5 2 (4) 2 5 (9) 9 .4597
Ear and labyrinth disorders 7 (13) 7 3 (5) 4 1 (2) 1 .0500
*Each subject is counted only once per preferred term, at the greatest severity.
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Table IV. Adverse events during wk 25-48
Body system and preferred term
D-2.5 mg (n = 46) E-5.0 mg (n = 46)
Placebo-2.5 mg
(n = 23)
Placebo-5.0 mg
(n = 23)
P value
Subjects
Events
Subjects
Events
Subjects
Events
Subjects
Eventsn* (%) n* (%) n* (%) n* (%)
All adverse events 43 (93) 353 42 (91) 409 23 (100) 212 21 (91) 182 .6006
Respiratory disorders 31 (67) 75 32 (70) 104 16 (70) 51 12 (52) 36 .5275
Cough 24 (52) 31 26 (57) 42 10 (43) 17 8 (35) 15 .3379
Sinus congestion 14 (30) 18 15 (33) 25 8 (35) 13 5 (22) 6 .8051
Rhinorrhea 4 (9) 6 13 (28) 17 6 (26) 9 6 (26) 10 .0704
Nasal congestion 7 (15) 7 6 (13) 10 3 (13) 6 2 (9) 3 .9545
Epistaxis 2 (4) 2 0 (0) 0 3 (13) 3 1 (4) 1 .0926
Psychiatric disorders 26 (57) 53 26 (57) 65 15 (65) 33 18 (78) 50 .2868
Aggression 11 (24) 16 12 (26) 17 5 (22) 10 7 (30) 10 .9156
Sleep disorder 8 (17) 9 7 (15) 12 4 (17) 5 5 (22) 5 .9256
Initial insomnia 4 (9) 4 7 (15) 8 3 (13) 3 3 (13) 3 .7799
Abnormal behavior 2 (4) 3 2 (4) 2 4 (17) 5 6 (26) 8 .0112
Terminal insomnia 3 (7) 3 3 (7) 3 3 (13) 3 3 (13) 3 .5812
Agitation 4 (9) 6 3 (7) 3 0 (0) 0 4 (17) 4 .1945
Affect lability 1 (2) 1 5 (11) 5 1 (4) 1 1 (4) 2 .3963
Anxiety 2 (4) 2 1 (2) 1 2 (9) 2 3 (13) 3 .2271
Gastrointestinal disorders 25 (54) 46 28 (61) 71 13 (57) 24 11 (48) 24 .7608
Vomiting 12 (26) 17 18 (39) 26 9 (39) 14 6 (26) 7 .4580
Diarrhea 13 (28) 14 12 (26) 15 2 (9) 2 6 (26) 7 .2901
Constipation 5 (11) 6 8 (17) 18 4 (17) 4 3 (13) 5 .8154
General disorders 22 (48) 36 25 (54) 40 16 (70) 27 10 (43) 18 .2709
Pyrexia 17 (37) 28 23 (50) 31 13 (57) 19 5 (22) 7 .0576
Irritability 7 (15) 7 4 (9) 4 3 (13) 4 6 (26) 7 .3021
Fatigue 0 (0) 0 2 (4) 2 1 (4) 1 3 (13) 3 .0926
Infections and infestations 26 (57) 53 24 (52) 39 11 (48) 22 9 (39) 22 .5860
Ear infection 6 (13) 7 7 (15) 9 7 (30) 8 3 (13) 3 .3299
Upper respiratory tract infection 4 (9) 8 6 (13) 11 4 (17) 7 3 (13) 8 .7571
Nervous system disorders 15 (33) 24 13 (28) 23 7 (30) 12 6 (26) 10 .9731
Psychomotor hyperactivity 5 (11) 6 5 (11) 5 5 (22) 8 3 (13) 3 .6247
Headache 5 (11) 6 2 (4) 5 1 (4) 1 2 (9) 2 .6988
Skin and subcutaneous tissue disorders 15 (33) 21 9 (20) 11 7 (30) 9 5 (22) 6 .5193
Rash 10 (22) 11 3 (7) 3 3 (13) 4 2 (9) 2 .1887
Metabolism and nutrition disorders 9 (20) 14 11 (24) 17 7 (30) 12 6 (26) 6 .7525
Decreased appetite 6 (13) 7 6 (13) 6 4 (17) 5 3 (13) 3 .9692
Increased appetite 4 (9) 5 7 (15) 10 5 (22) 7 2 (9) 2 .4356
Injury, poisoning, and procedural complications 7 (15) 10 7 (15) 9 3 (13) 3 2 (9) 2 .9422
Investigations 6 (13) 7 6 (13) 10 3 (13) 4 1 (4) 1 .7683
Ear and labyrinth disorders 1 (2) 1 6 (13) 7 1 (4) 1 2 (9) 2 .2078
Eye disorders 1 (2) 1 2 (4) 2 3 (13) 6 0 (0) 0 .1620
Musculoskeletal and connective tissue disorders 1 (2) 1 1 (2) 1 3 (13) 3 1 (4) 1 .1820
*Each subject is counted only once per preferred term, at the greatest severity.
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